^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq (atezolizumab)

    i
    Other names: MPDL3280A, RG7446, RO5541267, MPDL-3280A, RG-7446, RO 5541267, RO 554-1267, RG7446-42, RO-5541267, MPDL 3280A, RG 7446, RG744642, RG 744642, RG-744642, RO-5541267 IV, MPDL 3280A IV
    Company:
    Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    1d
    An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Aug 2026
    Enrollment closed • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR wild-type • ALK wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    2d
    Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    2d
    Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study. (PubMed, JTO Clin Res Rep)
    Effective predictors of response to atezolizumab plus carboplatin/etoposide (CE) therapy in extensive-stage SCLC (ES-SCLC) remain limited. mOS and mPFS were not significantly different between SCLC subtypes but were numerically shorter in the SCLC-N group. CD8+ TIL density is a potential biomarker of clinical benefit in ES-SCLC and may facilitate patient selection for atezolizumab combination therapy.
    Observational data • Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV
    2d
    A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (clinicaltrials.gov)
    P1/2, N=129, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • pumitamig (BNT327)
    3d
    Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan. (PubMed, Eur J Health Econ)
    Pembrolizumab is a cost-effective first-line treatment for advanced NSCLC with PD-L1 TPS ≥ 50% in Japan. Nivolumab plus ipilimumab is also a viable option. Atezolizumab is the least cost-effective.
    Journal • HEOR • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Cost-effectiveness
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab)
    3d
    A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2029 --> Aug 2027 | Trial primary completion date: Jun 2029 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    4d
    TOMBOLA: Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy (clinicaltrials.gov)
    P2, N=154, Active, not recruiting, Jørgen Bjerggaard Jensen | Recruiting --> Active, not recruiting | N=282 --> 154 | Trial completion date: Nov 2029 --> Nov 2030
    Enrollment closed • Enrollment change • Trial completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab)
    5d
    Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab. (PubMed, JHEP Rep)
    Our study provides clinical evidence supporting plasma GPC3 as a non-invasive biomarker in HCC, showing that circulating GPC3 levels are associated with tumor expression but more closely linked to clinical outcomes, serving as an independent predictor of survival and treatment response in patients treated with atezolizumab plus bevacizumab. These findings suggest that plasma-based assessment may complement tissue-based evaluation and support real-time risk stratification in advanced HCC, although further validation in diverse, prospective cohorts is warranted.
    Clinical data • Journal • PD(L)-1 Biomarker
    |
    GPC3 (Glypican 3)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    6d
    From Functional Group and Metabolite Analysis to Rational Design: Discovery of BXY-14 as a Highly Potent TLR2 Agonist with Enhanced Vaccine Adjuvants and Cancer Immunotherapy. (PubMed, J Med Chem)
    Additionally, in murine models, BXY-14 markedly downregulated intratumoral PD-L1 expression and demonstrated synergistic efficacy with the anti-PD-L1 monoclonal antibody atezolizumab, resulting in significantly prolonged overall survival. Together, this work establishes metabolically gated immunity and delivers a translational TLR2 agonist bridging bacterial metabolite chemistry with immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TLR2 (Toll Like Receptor 2)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab)
    7d
    Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Dwight Owen | Suspended --> Recruiting | Trial completion date: Dec 2026 --> Dec 2027
    Enrollment open • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • Erivedge (vismodegib)
    7d
    Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile Insights. (PubMed, Anticancer Res)
    A history of Ate/Bev therapy increased soluble MHC class I and sPD-L1 serum levels. Tre/Dur therapy may be useful as a first-line treatment for uHCC, and elevated sPD-L1 levels may attenuate Dur efficacy. This increase may impair tumor recognition and potentially reduce Tre/Dur therapy effectiveness despite activated cytotoxic T cells.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    9d
    ABSK-011-201: A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients (clinicaltrials.gov)
    P2, N=118, Enrolling by invitation, Abbisko Therapeutics Co, Ltd | Recruiting --> Enrolling by invitation | N=62 --> 118 | Trial completion date: Oct 2024 --> Dec 2029 | Trial primary completion date: Jul 2024 --> Dec 2028
    Enrollment status • Enrollment change • Trial completion date • Trial primary completion date
    |
    FGF19 (Fibroblast growth factor 19)
    |
    Tecentriq (atezolizumab) • Loqtorzi (toripalimab-tpzi) • irpagratinib (ABSK011)